Literature DB >> 18469643

Acute coagulopathy of trauma: hypoperfusion induces systemic anticoagulation and hyperfibrinolysis.

Karim Brohi1, Mitchell J Cohen, Michael T Ganter, Marcus J Schultz, Marcel Levi, Robert C Mackersie, Jean-François Pittet.   

Abstract

BACKGROUND: Coagulopathy is present at admission in 25% of trauma patients, is associated with shock and a 5-fold increase in mortality. The coagulopathy has recently been associated with systemic activation of the protein C pathway. This study was designed to characterize the thrombotic, coagulant and fibrinolytic derangements of trauma-induced shock.
METHODS: This was a prospective cohort study of major trauma patients admitted to a single trauma center. Blood was drawn within 10 minutes of arrival for analysis of partial thromboplastin and prothrombin times, prothrombin fragments 1 + 2 (PF1 + 2), fibrinogen, factor VII, thrombomodulin, protein C, plasminogen activator inhibitor-1 (PAI-1), thrombin activatable fibrinolysis inhibitor (TAFI), tissue plasminogen activator (tPA), and D-dimers. Base deficit was used as a measure of tissue hypoperfusion.
RESULTS: Two hundred eight patients were studied. Systemic hypoperfusion was associated with anticoagulation and hyperfibrinolysis. Coagulation was activated and thrombin generation was related to injury severity, but acidosis did not affect Factor VII or PF1 + 2 levels. Hypoperfusion-induced increase in soluble thrombomodulin levels was associated with reduced fibrinogen utilization, reduction in protein C and an increase in TAFI. Hypoperfusion also resulted in hyperfibrinolysis, with raised tPA and D-Dimers, associated with the observed reduction in PAI-1 and not alterations in TAFI.
CONCLUSIONS: Acute coagulopathy of trauma is associated with systemic hypoperfusion and is characterized by anticoagulation and hyperfibrinolysis. There was no evidence of coagulation factor loss or dysfunction at this time point. Soluble thrombomodulin levels correlate with thrombomodulin activity. Thrombin binding to thrombomodulin contributes to hyperfibrinolysis via activated protein C consumption of PAI-1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18469643     DOI: 10.1097/TA.0b013e318169cd3c

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  185 in total

1.  Clotting factor deficiency in early trauma-associated coagulopathy.

Authors:  Sandro B Rizoli; Sandro Scarpelini; Jeannie Callum; Bartolomeu Nascimento; Kenneth G Mann; Ruxandra Pinto; Jan Jansen; Homer C Tien
Journal:  J Trauma       Date:  2011-11

Review 2.  Protocols for massive blood transfusion: when and why, and potential complications.

Authors:  E Guerado; A Medina; M I Mata; J M Galvan; M L Bertrand
Journal:  Eur J Trauma Emerg Surg       Date:  2015-12-09       Impact factor: 3.693

3.  The tissue factor pathway mediates both activation of coagulation and coagulopathy after injury.

Authors:  Benjamin M Howard; Byron Y Miyazawa; Weifeng Dong; Wendy J Cedron; Ryan F Vilardi; Wolfram Ruf; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2015-12       Impact factor: 3.313

4.  Molecular intercommunication between the complement and coagulation systems.

Authors:  Umme Amara; Michael A Flierl; Daniel Rittirsch; Andreas Klos; Hui Chen; Barbara Acker; Uwe B Brückner; Bo Nilsson; Florian Gebhard; John D Lambris; Markus Huber-Lang
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

5.  Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.

Authors:  Alexander Y Mitrophanov; Alisa S Wolberg; Jaques Reifman
Journal:  Mol Biosyst       Date:  2014-07-29

6.  Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.

Authors:  Jessica C Cardenas; Xu Zhang; Erin E Fox; Bryan A Cotton; John R Hess; Martin A Schreiber; Charles E Wade; John B Holcomb
Journal:  Blood Adv       Date:  2018-07-24

7.  Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial.

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kevin McVaney; Gary Bryskiewicz; Robert Blechar; Theresa Chin; Clay Cothren Burlew; Fredric Pieracci; F Bernadette West; Courtney D Fleming; Arsen Ghasabyan; James Chandler; Christopher C Silliman; Anirban Banerjee; Angela Sauaia
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

8.  Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma.

Authors:  Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

9.  A Fibrin Cross-linking Polymer Enhances Clot Formation Similar to Factor Concentrates and Tranexamic Acid in an in vitro Model of Coagulopathy.

Authors:  Leslie W Chan; Nathan J White; Suzie H Pun
Journal:  ACS Biomater Sci Eng       Date:  2016-01-28

10.  Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective study.

Authors:  Lauren N Bell; Richard L Berg; John R Schmelzer; Hong Liang; Joseph J Mazza; Rajan Kanth; Christopher L Bray; Calixto B Zaldivar; Steven H Yale
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.